• Appropriate patient management, IgM and IgG results from same sample tube
    • Screening patients for B19V antibody status will determine the need for further follow-up.
    • An IgG-positive, IgM-negative pregnant women should be reassured that B19V infection is not a cause for concern during their pregnancy.
  • Confidence in the results
    • Selected recombinant VP2 antigen for optimal test performance
    • Traceable to the WHO IS 01/602 for IgG, with results express in IU/mL.
    • No observed cross-reactivity with common viruses such as EBV, VZV and CMV
  • Streamlined workflow, rapid results and cost effective
    • Ready to use, 50 tests reagents cartridge with up to 60 days on-board storage.
    • Calibrate once every 21 days with common controls for both IgM and IgG assays
    • Suitable for use with serum or plasma (sodium heparin, sodium citrate, potassium EDTA) samples.

IDS Parvovirus B19 IgG or IgM is an automated in-vitro diagnostics device intended for the semi-quantitative determination of specific IgG or IgM class antibodies directed against the Parvovirus B19 in human serum or plasma samples on the IDS system. Results are to be used for assessing the parvovirus B19 antibody status in individuals who may be at risk of infection from, or who have been infected with, parvovirus B19.

Parvovirus is a global and common infectious pathogen in humans. Transmission of infection occurs via the respiratory route and vertically from mother to foetus1. The disease manifestation at first infection can be mild childhood rash, Erythema Infectiosum (EI), and other possible complication2.

Serologic tests detect B19-specific IgM and IgG antibody directed against viral capsid antigen. In suspected acute infection, IgM antibodies are detected 10-12 days after infection, and IgG antibodies are detected at 2 weeks, EI patients have detectable IgM within 7 –10 days of exposure, which remains detectable for 2–3 months but can sometimes be detectable to 6 months post-infection3.

The most important role for parvovirus serology is in screening pregnant women. When they are exposed, they develop signs and symptoms of parvovirus B19 infection, IgG and IgM tests should be carried out for evidence of parvovirus infection.

1. Clinical Microbiology Reviews, July 2002, p. 485–505 Vol. 15, No. 3
2. Barbel Kaufmann, Alan A. Simpson and Michael G. Rossmann: The structure of human parvovirus B19; 11628–11633, PNAS, August 10, 2004 vol. 101no. 32
3. Anneke C. Dijkmansa,b, Eveline P. de Jongc, Ben A.C. Dijkmansd, Enrico Loprioree, Ann Vossena, Frans J. Walthere, and Dick Oepkes: Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications; Curr Opin Obstet Gynecol 2012, 24:95–101